Medpace (NASDAQ:MEDP) Given New $500.00 Price Target at Barclays

Medpace (NASDAQ:MEDP) had its price target reduced by investment analysts at Barclays from $525.00 to $500.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has an “underweight” rating on the stock. Barclays‘s price objective would indicate a potential upside of 16.94% from the stock’s previous close.

MEDP has been the topic of a number of other reports. Robert W. Baird upgraded shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 target price on the stock in a research note on Tuesday. Truist Financial lowered their price target on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a report on Wednesday. BMO Capital Markets set a $460.00 price objective on Medpace in a research note on Wednesday. Leerink Partners reduced their price objective on Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday. Finally, Zacks Research lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Three equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Medpace presently has an average rating of “Hold” and a consensus price target of $484.45.

Medpace Stock Performance

Shares of MEDP stock opened at $427.58 on Wednesday. The stock has a 50 day moving average price of $575.55 and a 200 day moving average price of $539.56. Medpace has a 52-week low of $250.05 and a 52-week high of $628.92. The firm has a market capitalization of $12.04 billion, a P/E ratio of 28.11, a P/E/G ratio of 1.78 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. The business had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. Medpace had a return on equity of 127.72% and a net margin of 17.83%.The business’s revenue was up 32.0% compared to the same quarter last year. During the same quarter last year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts forecast that Medpace will post 12.29 EPS for the current year.

Insider Buying and Selling at Medpace

In other Medpace news, CEO August J. Troendle sold 59,025 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the transaction, the chief executive officer directly owned 774,602 shares in the company, valued at approximately $470,787,603.56. The trade was a 7.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 296,880 shares of company stock valued at $178,815,404. Corporate insiders own 20.30% of the company’s stock.

Institutional Investors Weigh In On Medpace

A number of hedge funds and other institutional investors have recently bought and sold shares of MEDP. AQR Capital Management LLC grew its holdings in Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Norges Bank acquired a new stake in shares of Medpace in the 2nd quarter worth $66,597,000. Arrowstreet Capital Limited Partnership grew its stake in Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after buying an additional 211,411 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Medpace by 92.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock worth $194,920,000 after buying an additional 166,654 shares during the last quarter. Finally, Clarkston Capital Partners LLC acquired a new position in Medpace during the 2nd quarter valued at about $40,569,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Robert W. Baird upgraded MEDP from “neutral” to “outperform” and set a $564 price target, signaling renewed buy-side enthusiasm. Baird Upgrade
• Positive Sentiment: Medpace won a CRO contract from Zelluna to run the first‑in‑human trial for ZIMA‑101 — a new business‑development win that supports future revenue pipeline. Zelluna CRO Win
• Positive Sentiment: Q4 results and FY2026 guidance beat/raise: Q4 EPS $4.67 vs $4.18 est., revenue $708.5M (up 32% YoY). Management set FY‑2026 EPS guidance of $16.68–$17.50 and revenue $2.8–2.9B, above consensus — supportive for forward earnings expectations. Earnings Release
• Neutral Sentiment: Truist trimmed its PT slightly to $539 and kept a “hold” rating — a modest change that is less bearish than some other dealer moves. Truist Note
• Neutral Sentiment: Market commentary highlights a strong quarter but flags a slow backlog — analysts note book‑to‑bill strength but a “stale backlog” that could limit upside until sales acceleration resumes. SA Analysis
• Negative Sentiment: Leerink Partners cut its price target from $575 to $485 and moved MEDP to “market perform,” which likely pressured sentiment given the size of the cut. Leerink PT Cut
• Negative Sentiment: Shares fell intraday despite the beat — headlines and analyst caution on backlog/growth cadence triggered a roughly 5% pullback as traders digested the guidance details and valuation. Investing.com
• Negative Sentiment: Coverage pieces called out a “key negative” element that tempered the headline beat (backlog normalization and shifts in metabolic trials), which investors are parsing for sustainability of revenue growth. MSN

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.